Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | RAPGEF3 | O95398 | 3/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 4/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191684 | 1.00 | PARP1 (0.39) | PARP1MAP4K1RAPGEF3RAPGEF4MAPK1 | |
| SCHEMBL20528263 | 0.81 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL20528226 | 0.81 | — | — | |
| SCHEMBL18191725 | 0.81 | — | — | |
| SCHEMBL29686617 | 0.81 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL20528265 | 0.81 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL21522934 | 0.80 | NOTUM (0.32) | — | |
| SCHEMBL29687057 | 0.80 | HDAC1 (0.39) | P2RX7 | |
| SCHEMBL20528243 | 0.80 | HDAC1 (0.39) | P2RX7 | |
| SCHEMBL20528242 | 0.80 | HDAC1 (0.39) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-107849012-B | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450316-B2 | Certain protein kinase inhibitor | CDK4, CDK6, CDK2 | PARP1 709/4885MAP4K1 109/4885RAPGEF3 2322/4885 |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | CDK4, CDK6, CDK2 | PARP1 699/4885MAP4K1 144/4885RAPGEF3 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.